CCM
CMPI

CAAS Capital Management’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

CAAS Capital Management’s Portfolio CMPI Stock Details CMPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-44,966
Closed -$518K – 964
2020
Q3 		$518K Buy
+44,966
New +$576K 0.01% 389

Other funds holding CMPI

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

CAAS Capital Management's CMPI Position: Q4 2020 in Review

CAAS Capital Management sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q4 2020, closing a stake of 44,966 shares — an estimated $518K sold.

CAAS Capital Management first reported a position in CMPI in Q3 2020 and held it in 1 quarter. The position peaked at $518K in Q3 2020. 36 funds tracked by Wall St. Rank hold CMPI as of Q4 2020.

  • CAAS Capital Management reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • CAAS Capital Management sold 44,966 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q4 2020, an estimated $518K.
  • CAAS Capital Management first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 1 quarter.
  • CAAS Capital Management's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $518K in Q3 2020.
  • 36 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q4 2020.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.